Summary of outcomes for the whole cohort and stratified according to the presence/absence and the amount of fibrosis
| No fibrosis | Fibrosis | All patients | Presence of fibrosis | Amount of Fibrosis* | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Outcome measure, n (%) | 240 (33.8) | 471 (66.2) | 711 | HR | 95% CI | p Value | HR | 95% CI | p Value | ||
| SCD or aborted SCD | 4 (1.7) | 18 (3.8) | 22 (3.1) | 2.69 | 0.91 | 7.97 | 0.073 | 1.24 | 1.06 | 1.45 | 0.007 |
| Cardiovascular death or aborted SCD | 8 (3.3) | 30 (6.4) | 38 (5.3) | 2.24 | 1.03 | 4.89 | 0.043 | 1.26 | 1.12 | 1.41 | <0.001 |
| Heart failure death | 4 (1.7) | 10 (2.1) | 14 (2.0) | 1.49 | 0.47 | 4.78 | 0.498 | 1.23 | 1.02 | 1.48 | 0.028 |
| SCD | 1 (0.4) | 8 (1.7) | 9 (1.3) | 4.92 | 0.61 | 39.3 | 0.134 | 1.27 | 0.99 | 1.62 | 0.056 |
| Aborted SCD | 3 (1.3) | 10 (2.1) | 13 (1.8) | 1.96 | 0.54 | 7.13 | 0.307 | 1.22 | 1.00 | 1.50 | 0.054 |
| Thromboembolic stroke | 0 (0) | 2 (0.4) | 2 (0.3) | – | – | – | – | – | – | – | – |
| All-cause mortality | 16 (6.7) | 39 (8.3) | 55 (7.7) | 1.44 | 0.81 | 2.58 | 0.218 | 1.11 | 0.99 | 1.24 | 0.068 |
SCD, sudden cardiac death.
*HRs per 5% of LV mass with late gadolinium enhancement.